Abstract:After the publication of the article "Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization" by Kerry J. Savage and Laurence de Leval in the December 2023 issue, 1 we realized that an error had been made in Table 1. The correct table is shown below. The Editorial Office apologize for the inconvenience.

Erratum: Trends in the global immuno-oncology landscape

Erratum: Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Erratum: Immunotherapy for Glioblastoma: Current Progress and Challenges

Erratum to: Topoisomerase IIα controls the decatenation checkpoint (Nature Cell Biology, (2009), 11, 2, (204-210), 10.1038/ncb1828)

Erratum: Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics [Corrigendum]

Correction Notice: Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL

Erratum: First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax)

Erratum to : Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Erratum: Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs

Correction To: Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells: the Effect of Combining RNA Interference with Tyrosine Kinase Inhibitors or Cetuximab

Erratum: Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study.

Author correction to ‘Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers’ [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

Erratum: IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment

Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Erratum: Approaching hemophagocytic lymphohistiocytosis

Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer

Erratum: Thadi A.; et al. Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. Vaccines 2018, 6, 54

Erratum: "Interferon-γ liposome: a new system to improve drug delivery in the treatment of lung cancer". Maysa Alhawamdeh, Mohammad Isreb, Abid Aziz, Badie K. Jacob, Diana Anderson and Mojgan Najafzadeh. ERJ Open Res 2021; 7: 00555-2020

Correction To: Gamma-delta (γδ) T Cells: Friend or Foe in Cancer Development?